Adds share movement in paragraph 2, disease background in paragraph 3, trial details in paragraphs 4-5
Jan 15 (Reuters) - Keros Therapeutics KROS.O said on Wednesday it would voluntarily halt testing of its experimental blood pressure treatment due to safety concerns during a mid-stage trial.
Its shares fell 8% to $11.52 in premarket trading.
The company was testing the therapy, cibotercept, in patients with pulmonary arterial hypertension — a rare, progressive lung disease that causes high blood pressure in the pulmonary arteries.
Keros said it observed excess fluid build up around the heart in patients. It is terminating the trial early and will monitor patients who were part of the study.
The company expects to present clinical data from the trial in the second quarter of 2025.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。